Skip to main content
SpringerLink
Log in
Book cover

Cytokines and Cancer pp 313–331Cite as

Cytokines in the Treatment of Acute Leukemias

  • Chapter

  • 821 Accesses

Part of the book series: Cancer Treatment and Research ((CTAR,volume 126))

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996; 88:3675–85.

    PubMed  CAS  Google Scholar 

  2. Geller RB. Use of cytokines in the treatment of acute myelocytic leukemia: a critical review. J Clin Oncol 1996; 14:1371–82.

    PubMed  CAS  Google Scholar 

  3. Estey EH. Growth factors in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14:175–87.

    Article  PubMed  CAS  Google Scholar 

  4. Rowe JM, Liesveld JL. Hematopoietic growth factors in acute leukemia. Leukemia 1997; 11:328–41.

    Article  PubMed  CAS  Google Scholar 

  5. Schiffer CA. Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia. N Engl J Med 2003; 349:727–9.

    Article  PubMed  Google Scholar 

  6. Miyauchi J, Kelleher CA, Wang C, Minkin S, McCulloch EA. Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture. Blood 1989; 73:1272–8.

    PubMed  CAS  Google Scholar 

  7. Cannistra SA, Groshek P, Griffin JD. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989; 3:328–34.

    PubMed  CAS  Google Scholar 

  8. Bhalla K, Holladay C, Arlin Z, Grant S, Ibrado AM, Jasiok M. Treatment with interleukin-3 plus granulocyte-macrophage colony-stimulating factors improves the selectivity of Ara-C in vitro against acute myeloid leukemia blasts. Blood 1991; 78:2674–9.

    PubMed  CAS  Google Scholar 

  9. te Boekhorst PA, Lowenberg B, Vlastuin M, Sonneveld P. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia 1993; 7:1191–8.

    Google Scholar 

  10. Inatomi Y, Toyama K, Clark SC, Shimizu K, Miyauchi J. Combinations of stem cell factor with other hematopoietic growth factors enhance growth and sensitivity to cytosine arabinoside of blast progenitors in acute myelogenous leukemia. Cancer Res 1994; 54:455–62.

    PubMed  CAS  Google Scholar 

  11. Hiddemann W, Kiehl M, Zuhlsdorf M, et al. Granulocyte-macrophage colony-stimulating factor and interleukin-3 enhance the incorporation of cytosine arabinoside into the DNA of leukemic blasts and the cytotoxic effect on clonogenic cells from patients with acute myeloid leukemia. Semin Oncol 1992; 19:31–7.

    PubMed  CAS  Google Scholar 

  12. Stone RM, Berg DT, George SL, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995; 332:1671–7.

    Article  PubMed  CAS  Google Scholar 

  13. Rowe JM, Andersen JW, Mazza JJ, et al. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood 1995; 86:457–62.

    PubMed  CAS  Google Scholar 

  14. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 1995; 332:1678–83.

    Article  PubMed  CAS  Google Scholar 

  15. Godwin JE, Kopecky KJ, Head DR, et al. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: a Southwest oncology group study (9031). Blood 1998; 91:3607–15.

    PubMed  CAS  Google Scholar 

  16. Heil G, Hoelzer D, Sanz MA, et al. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood 1997; 90:4710–8.

    PubMed  CAS  Google Scholar 

  17. Bradstock K, Matthews J, Young G, et al. Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia 2001; 15:1331–8.

    Article  PubMed  CAS  Google Scholar 

  18. Usuki K, Urabe A, Masaoka T, et al. Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia: a multicentre randomized study. Br J Haematol 2002; 116:103–12.

    Article  PubMed  CAS  Google Scholar 

  19. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML 1 trial. Blood 2001; 98:1302–11.

    Article  PubMed  CAS  Google Scholar 

  20. Harousseau JL, Witz B, Lioure B, et al. Granulocyte colony-stimulating factor after intensive consolidation chemotherapy in acute myeloid leukemia: results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques. J Clin Oncol 2000; 18:780–7.

    PubMed  CAS  Google Scholar 

  21. Lowenberg B, Boogaerts MA, Daenen SM, et al. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia. J Clin Oncol 1997; 15:3496–506.

    PubMed  CAS  Google Scholar 

  22. Moore JO, Dodge RK, Amrein PC, et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood 1997; 89:780–8.

    PubMed  CAS  Google Scholar 

  23. Zittoun R, Suciu S, Mandelli F, et al. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group. J Clin Oncol 1996; 14:2150–9.

    PubMed  CAS  Google Scholar 

  24. Bennett CL, Hynes D, Godwin J, Stinson TJ, Golub RM, Appelbaum FR. Economic analysis of granulocyte colony stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): estimates from a Southwest Oncology Group clinical trial. Cancer Invest 2001; 19:603–10.

    Article  PubMed  CAS  Google Scholar 

  25. Bennett CL, Stinson TJ, Tallman MS, et al. Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490). Ann Oncol 1999; 10:177–82.

    Article  PubMed  CAS  Google Scholar 

  26. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341:1051–62.

    Article  PubMed  CAS  Google Scholar 

  27. Cannistra SA, DiCarlo J, Groshek P, et al. Simultaneous administration of granulocyte-macrophage colony-stimulating factor and cytosine arabinoside for the treatment of relapsed acute myeloid leukemia. Leukemia 1991; 5:230–8.

    PubMed  CAS  Google Scholar 

  28. Witz F, Sadoun A, Perrin MC, et al. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1998; 91:2722–30.

    PubMed  CAS  Google Scholar 

  29. Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003; 349:743–52.

    Article  PubMed  Google Scholar 

  30. Lowenberg B, Suciu S, Archimbaud E, et al. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 1997; 90:2952–61.

    PubMed  CAS  Google Scholar 

  31. Heil G, Chadid L, Hoelzer D, et al. GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML). Leukemia 1995; 9:3–9.

    PubMed  CAS  Google Scholar 

  32. Hast R, Hellstrom-Lindberg E, Ohm L, et al. No benefit from adding GM-CSF to induction chemotherapy in transforming myelodysplastic syndromes: better outcome in patients with less proliferative disease. Leukemia 2003; 17:1827–33.

    Article  PubMed  CAS  Google Scholar 

  33. Uyl-de Groot CA, Lowenberg B, Vellenga E, Suciu S, Willemze R, Rutten FF. Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia. Br J Haematol 1998; 100:629–36.

    Article  Google Scholar 

  34. Ohno R, Naoe T, Kanamaru A, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 1994; 83:2086–92.

    PubMed  CAS  Google Scholar 

  35. Thomas X, Fenaux P, Dombret H, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 Trial). Leukemia 1999; 13:1214–20.

    Article  PubMed  CAS  Google Scholar 

  36. Rossi HA, O'Donnell J, Sarcinelli F, Stewart FM, Quesenberry PJ, Becker PS. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming with successive concomitant low-dose Ara-C for elderly patients with secondary/refractory acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2002; 16:310–5.

    Article  PubMed  CAS  Google Scholar 

  37. He XY, Pohlman B, Lichtin A, Rybicki L, Kalaycio M. Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia. Leukemia 2003; 17:1078–84.

    Article  PubMed  CAS  Google Scholar 

  38. Jahns-Streubel G, Reuter C, Auf der Landwehr U, et al. Activity of thymidine kinase and of polymerase alpha as well as activity and gene expression of deoxycytidine deaminase in leukemic blasts are correlated with clinical response in the setting of granulocyte-macrophage colony-stimulating factor-based priming before and during TAD-9 induction therapy in acute myeloid leukemia. Blood 1997; 90:1968–76.

    PubMed  CAS  Google Scholar 

  39. Pui CH, Campana D, Evans WE. Childhood acute lymphoblastic leukaemia—current status and future perspectives. Lancet Oncol 2001; 2:597–607.

    Article  PubMed  CAS  Google Scholar 

  40. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003; 98:1337–54.

    Article  PubMed  Google Scholar 

  41. Hoelzer D, Gokbuget N. New approaches to acute lymphoblastic leukemia in adults: where do we go? Semin Oncol 2000; 27:540–59.

    PubMed  CAS  Google Scholar 

  42. Kantarjian HM, Estey E, O'Brien S, et al. Granulocyte colony-stimulating factor supportive treatment following intensive chemotherapy in acute lymphocytic leukemia in first remission. Cancer 1993; 72:2950–5.

    PubMed  CAS  Google Scholar 

  43. Bassan R, Lerede T, Di Bona E, et al. Granulocyte colony-stimulating factor (G-CSF, filgrastim) after or during an intensive remission induction therapy for adult acute lymphoblastic leukaemia: effects, role of patient pretreatment characteristics, and costs. Leuk Lymphoma 1997; 26:153–61.

    Article  PubMed  CAS  Google Scholar 

  44. Ottmann OG, Ganser A, Freund M, et al. Simultaneous administration of granulocyte colony-stimulating factor (Filgrastim) and induction chemotherapy in acute lymphoblastic leukemia. A pilot study. Ann Hematol 1993; 67:161–7.

    Article  PubMed  CAS  Google Scholar 

  45. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18:547–61.

    PubMed  CAS  Google Scholar 

  46. Welte K, Reiter A, Mempel K, et al. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Munster Study Group. Blood 1996; 87:3143–50.

    PubMed  CAS  Google Scholar 

  47. Laver J, Amylon M, Desai S, et al. Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. J Clin Oncol 1998; 16:522–6.

    PubMed  CAS  Google Scholar 

  48. Clarke V, Dunstan FD, Webb DK. Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. Med Pediatr Oncol 1999; 32:331–5.

    Article  PubMed  CAS  Google Scholar 

  49. Michel G, Landman-Parker J, Auclerc MF, et al. Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18:1517–24.

    PubMed  CAS  Google Scholar 

  50. Little MA, Morland B, Chisholm J, et al. A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. Med Pediatr Oncol 2002; 38:98–103.

    Article  PubMed  CAS  Google Scholar 

  51. Heath JA, Steinherz PG, Altman A, et al. Human granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: a Children's Cancer Group Study. J Clin Oncol 2003; 21:1612–7.

    Article  PubMed  CAS  Google Scholar 

  52. Pui CH, Boyett JM, Hughes WT, et al. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. N Engl J Med 1997; 336:1781–7.

    Article  PubMed  CAS  Google Scholar 

  53. Ottmann OG, Hoelzer D, Gracien E, et al. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: a randomized phase III trial. Blood 1995; 86:444–50.

    PubMed  CAS  Google Scholar 

  54. Ohno R, Tomonaga M, Ohshima T, et al. A randomized controlled study of granulocyte colony stimulating factor after intensive induction and consolidation therapy in patients with acute lymphoblastic leukemia. Japan Adult Leukemia Study Group. Int J Hematol 1993; 58:73–81.

    PubMed  CAS  Google Scholar 

  55. Geissler K, Koller E, Hubmann E, et al. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia—a randomized phase-III study. Blood 1997; 90:590–6.

    PubMed  CAS  Google Scholar 

  56. Larson RA, Dodge RK, Linker CA, et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. Blood 1998; 92:1556–64.

    PubMed  CAS  Google Scholar 

  57. Ifrah N, Witz F, Jouet JP, et al. Intensive short term therapy with granulocyte-macrophage-colony stimulating factor support, similar to therapy for acute myeloblastic leukemia, does not improve overall results for adults with acute lymphoblastic leukemia. GOELAMS Group. Cancer 1999; 86:1496–505.

    Article  PubMed  CAS  Google Scholar 

  58. Holowiecki J, Giebel S, Krzemien S, et al. G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study. Leuk Lymphoma 2002; 43:315–25.

    Article  PubMed  CAS  Google Scholar 

  59. Delorme J, Badin S, Le Corroller AG, et al. Economic evaluation of recombinant human granulocyte colony-stimulating factor in very high-risk childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2003; 25:441–7.

    Article  PubMed  Google Scholar 

  60. Lotzova E, Savary CA, Herberman RB. Inhibition of clonogenic growth of fresh leukemia cells by unstimulated and IL-2 stimulated NK cells of normal donors. Leuk Res 1987; 11:1059–66.

    Article  PubMed  CAS  Google Scholar 

  61. Oshimi K, Oshimi Y, Akutsu M, et al. Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 1986; 68:938–48.

    PubMed  CAS  Google Scholar 

  62. Margolin K, Forman SJ. Immunotherapy with interleukin-2 after hematopoietic cell transplantation for hematologic malignancy. Cancer J Sci Am 2000; 6Suppl 1:S33–8.

    PubMed  Google Scholar 

  63. Foa R, Meloni G, Tosti S, et al. Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot study. Br J Haematol 1991; 77:491–6.

    Article  PubMed  CAS  Google Scholar 

  64. Meloni G, Foa R, Vignetti M, et al. Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 1994; 84:2158–63.

    PubMed  CAS  Google Scholar 

  65. Meloni G, Vignetti M, Pogliani E, et al. Interleukin-2 therapy in relapsed acute myelogenous leukemia. Cancer J Sci Am 1997; 3Suppl 1:S43–7.

    PubMed  Google Scholar 

  66. Goodman M, Cabral L, Cassileth P. Interleukin-2 and leukemia. Leukemia 1998; 12:1671–5.

    Article  PubMed  CAS  Google Scholar 

  67. Bergmann L, Heil G, Kolbe K, et al. Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. Leuk Lymphoma 1995; 16:271–9.

    PubMed  CAS  Google Scholar 

  68. Meloni G, Vignetti M, Andrizzi C, Capria S, Foa R, Mandelli F. Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: updated experience with 20 cases. Leuk Lymphoma 1996; 21:429–35.

    PubMed  CAS  Google Scholar 

  69. Soiffer RJ, Murray C, Cochran K, et al. Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation. Blood 1992; 79:517–26.

    PubMed  CAS  Google Scholar 

  70. Soiffer RJ, Murray C, Gonin R, Ritz J. Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation. Blood 1994; 84:964–71.

    PubMed  CAS  Google Scholar 

  71. Klingemann HG, Phillips GL. Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia? Leuk Lymphoma 1995; 16:397–405.

    PubMed  CAS  Google Scholar 

  72. Robinson N, Sanders JE, Benyunes MC, et al. Phase I trial of interleukin-2 after unmodified HLA-matched sibling bone marrow transplantation for children with acute leukemia. Blood 1996; 87:1249–54.

    PubMed  CAS  Google Scholar 

  73. Blaise D, Attal M, Pico JL, et al. The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission. Leuk Lymphoma 1997; 25:469–78.

    PubMed  CAS  Google Scholar 

  74. Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 1995; 86:1619–28.

    PubMed  CAS  Google Scholar 

  75. Cortes JE, Kantarjian HM, O'Brien S, et al. A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission. Cancer 1999; 85:1506–13.

    Article  PubMed  CAS  Google Scholar 

  76. Farag SS, George SL, Lee EJ, et al. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. Clin Cancer Res 2002; 8:2812–9.

    PubMed  CAS  Google Scholar 

  77. Sievers EL, Lange BJ, Sondel PM, et al. Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: a report from the Children's Cancer Group. J Clin Oncol 1998; 16:914–9.

    PubMed  CAS  Google Scholar 

  78. Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000; 95:2530–5.

    PubMed  CAS  Google Scholar 

  79. Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999; 94:3694–701.

    PubMed  CAS  Google Scholar 

  80. Estey EH, Thall PF, Giles FJ, et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. Blood 2002; 99:4343–9.

    Article  PubMed  CAS  Google Scholar 

  81. Ellis M, Zwaan F, Hedstrom U, et al. Recombinant human interleukin 11 and bacterial infection in patients with [correction of] haematological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361:275–80.

    Article  PubMed  CAS  Google Scholar 

  82. Estey E, Andreeff M. Phase II study of interleukin-6 in patients with smoldering relapse of acute myelogenous leukemia. Leukemia 1995; 9:1440–3.

    PubMed  CAS  Google Scholar 

  83. Nemunaitis J, Ross M, Meisenberg B, et al. Phase I study of recombinant human interleukin-1 beta (rhIL-1 beta) in patients with bone marrow failure. Bone Marrow Transplant 1994; 14:583–8.

    PubMed  CAS  Google Scholar 

  84. Preisler HD, Li B, Yang BL, et al. Suppression of telomerase activity and cytokine messenger RNA levels in acute myelogenous leukemia cells in vivo in patients by amifostine and interleukin 4. Clin Cancer Res 2000; 6:807–12.

    PubMed  CAS  Google Scholar 

  85. Frankel AE, Powell BL, Hall PD, Case LD, Kreitman RJ. Phase I trial of a novel diphtheria toxin/granulocyte macrophage colony-stimulating factor fusion protein (DT388GMCSF) for refractory or relapsed acute myeloid leukemia. Clin Cancer Res 2002; 8:1004–13.

    PubMed  CAS  Google Scholar 

  86. Black JH, McCubrey JA, Willingham MC, Ramage J, Hogge DE, Frankel AE. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice. Leukemia 2003; 17:155–9.

    Article  PubMed  CAS  Google Scholar 

  87. Estey EH, Thall PF, Pierce S, et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/-all-trans retinoic acid +/-granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999; 93:2478–84.

    PubMed  CAS  Google Scholar 

  88. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood 2004; 103:479–85.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Texas M. D. Anderson Cancer Center, Houston, Texas

    Farhad Ravandi & Partow Kebriaei

Authors
  1. Farhad Ravandi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Partow Kebriaei
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, 710 N. Fairbanks Court, Olson 8256, Chicago, IL, 60611, USA

    Leonidas C. Platanias MD, PhD

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Ravandi, F., Kebriaei, P. (2005). Cytokines in the Treatment of Acute Leukemias. In: Platanias, L.C. (eds) Cytokines and Cancer. Cancer Treatment and Research, vol 126. Springer, Boston, MA. https://doi.org/10.1007/0-387-24361-5_13

Download citation

  • DOI: https://doi.org/10.1007/0-387-24361-5_13

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-24360-3

  • Online ISBN: 978-0-387-24361-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation